Why the Dementia Epidemic is Actually Shrinking

Few medical conditions terrify us quite like dementia. Alzheimer’s, the most common culprit, is especially cruel because of its sneaky, relentless nature. It strips away a person’s sense of self, leaving heartbroken loved ones to care for a stranger. The late singer Glen Campbell, who suffered from Alzheimer’s, captured this horror perfectly: “I’m still here, but yet I’m gone […] They never defined who I am, the man that loves you ‘til the end […] You’re never gonna see it in my eyes, it’s not gonna hurt me when you cry. […] I’m not gonna miss you.”

We also dread it because we assume it’s waiting for all of us. For years, gloomy forecasters have fanned these fears. Combine an ageing global population with rising life expectancy, and the math looks terrifying. One widely cited study predicted global dementia cases would nearly triple, jumping from 57 million in 2019 to 153 million by 2050. Others warned of an economic catastrophe, projecting that the global cost of care and human suffering could hit an eye-watering $16.9 trillion by mid-century.

Yet those terrifying graphs are almost certainly wrong. If you look closely at rich countries today, a very different story is emerging.

Why were the doom-mongers wrong?

When American actuary Eric Stallard first looked at dementia rates among elderly Americans a decade ago, the number shocked him. In fact, he held off publishing his work for two and a half years just to double-check his maths. He wanted to be certain, because his findings completely defied the usual doomsday narrative.

Instead of an intensifying plague, the share of older people succumbing to dementia was shrinking fast. Last year, Stallard and his colleagues published research showing that 40 years ago, three in every ten Americans aged 85 to 89 had dementia. By 2024, that figure has dropped to just one in ten.

America is hardly an outlier. Across six countries in North America and Europea, the share of older people diagnosed with dementia fell by 13% per decade between 1988 and 2015, according to a massive study by Frank Wolters at the Erasmus Medical Centre in Rotterdam. Data from the famous Framingham Heart Study tell an even more dramatic story, showing a 20% drop in new dementia cases per decade over roughly 40 years. Folks entering their golden years in 2013 were 44% less likely to have dementia than those reaching the same age in 1978.

Why did the old models miss this? Most earlier projections simply pooled elderly people together and assumed that age-adjusted risk would never change. But when researchers looked at narrow birth cohorts over time, they found that dementia rates have been dropping by 2.5% to 3% with each passing calendar year.

Even a tiny annual drop makes a massive difference over time. At the Erasmus Medical Centre, researchers built a computer simulation of 10 million Dutch people. Under the old assumption (that dementia risk never changes) cases more than doubled by 2050. But when they factored in Wolters’s 13% decadal drop, the future looked much brighter. Yes, total cases still rose due to a growing elderly population, but they grew by just 43% above 2020 levels, rather than doubling. The predicted epidemic is simply not happening.

How did a Finnish heart project change everything we know about brain health?

To understand why our brains are holding up better, we have to look back at a rugged, remote part of 1970s Finland called North Karelia. Back then, the region had one of the world’s highest rates of heart attacks. Desperate to stop the rot, health authorities launched an aggressive campaign: they told people to stub out the cigarettes, and monitor their blood pressure, and eat healthier food.

It worked brilliantly, cutting heart attack deaths by 84%. But it also gave researchers 40 years of detailed medical records for a large population. When scientists sifted through that data, they found solid proof that high blood pressure, high cholesterol, obesity, and poor fitness in mid-life all drove up the risk of dementia 20 years later.

This revelations changed everything. Dementia was not just a random meteorite hitting old people from outer space. It was the end stage of a long physical process that began decades earlier, which meant it could be slowed down or even stopped.

To prove this beyond a doubt, Finnish researchers launched the world’s first major randomised controlled trial (the gold standard of science) to see if lifestyle changes could save the brain. The FINGER study (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) took older people at high risk of decline and put them on a two-year regimen of healthy eating, exercise, brain training, and heart care.

The 2015 results were a triumph: people who changed their daily habits significantly reduced their risk of cognitive decline. Similar trials across America, Australia, and Japan have backed this up.

Better yet, these lifestyle upgrades work even against bad genetics. Roughly 25% of us carry a single copy of the ApoE4 gene, which doubled or triples the risk of Alzheimer’s. For the 2% to 3% who carry two copies, the risk jumps 10 to 15 times. Yet the FINGER data showed that people with the ApoE4 gene actually gained a bigger benefit from lifestyle changes than those without it. You cannot swap your DNA, but you can certainly outrun it.

What simple habits actually protect our minds?

Today, the international Lancet Commission on Dementia reckons we can delay or prevent up to 45% of all dementia cases worldwide just by tackling 14 modifiable risk factors across our lives.

Some of these are obvious: eat well, exercise, and stop smoking. Others are surprising. Getting a good education in childhood is massive, as poor schooling links to a 60% higher dementia risk later on. In mid-life, treating depression is vital; leaving it unchecked more than doubles your risk. Fixing hearing loss and lowering high LDL cholesterol could single-handedly wipe out 14% of all global dementia cases. Even simple hygiene helps, like flossing your teeth regularly to stop gum inflammation from damaging your brain.

The researchers did issue one warning: sleep loss might be a risk factor, but obsessing over it just gives anxious insomniacs one more thing to lose sleep over. They also noted a cheeky paradox regarding careers. People with demanding, highly engaging jobs (like medical researchers and journalists) keep their brains naturally nimble without needing sudoku puzzles. However, those same jobs generate high stress, which might turn out to be a risk factors in its own right.

Ultimately, we are already reaping the rewards of broader public health wins. Decades of anti-smoking drives, blood pressure pills, better schooling, and heart attack prevention have, by happy accident, built us stronger, more resilient brains.

Could a basic shingles jab really stop the mind from fading?

When hitting the gym and eating greens takes years of dedication, scientists recently uncovered a powerful shortcut that involved almost no sweat at all: the shingles vaccine.

This discovery came from a fascinating natural experiment in Wales. In 2013, the British health service started offering free shingles jabs to people aged 70 to 79. Because of strict birthdate cutoffs, people who had just turned 80 missed out, while those just a few weeks younger got the jab. Stanford University researchers compared the two groups and spotted something remarkable: the vaccinated group saw their dementia risk drop by 20% for at least seven years. A newer study by the same team suggests the vaccine even slows down the disease in people who already have it.

Why does a common chickenpox vaccine protect the brain? Scientists have two theories. One is that the varicella-zoster virus (which causes shingles and chickenpox) quietly causes nerve damage and brain inflammation even when it seems dormant. Stopping the virus stop the brain damage. The second theory is that the vaccine simply gives the immune system a firm kick up the B-cells, waking it up to fight off other brain-invading bugs.

Most of this evidence comes from an older live-virus vaccine, which has since been replaced by a safer, synthetic version called Shingrix. Early data suggest this new jab might be just as powerful against dementia, if not better.

Yet governments are inexplicably dragging their feet. A full two-dose course of Shingrix costs Britain’s NHS about £320 (around £460 if bought privately at a pharmacy), and American federal programmes pay about $270. That is absolute peanuts compared to the crushing long-term cost of dementia care. Even taking into account only the shingles cases prevented, studies show it is cost-effective to vaccinate everyone from age 55. Yet Britain only recently lowered its eligibility age from 70 to 65, and it has been painfully slow to roll it out. Across the EU, only 17 of 27 countries recommend the jab at all, and many restrict it to the over-65s.

In the Philippines, the shingles jab is completely missing from the free immunisation programme for senior citizens, which prioritises cheaper basics like flu and pneumonia shots. A Filipino grandparent who wants Shingrix must visit a private clinic and pay roughly ₱16,000 to ₱20,000 for the two doses. Many Filipino seniors survive on modest pensions. Charging them a month’s wage for a brain-protecting shot is a bitter pill to swallow.

Studies show that preventing shingles alone makes it cost-effective to vaccinate everyone from age 55. Add the huge bonus of dodging one in five future dementia cases, and rationing such a cheap, brain-saving tool to save upfront pennies for wealthy governments make zero sense. Meanwhile, developing nations are priced out entirely.

What about miracle weight-loss drugs and new Alzheimer’s treatments?

While prevention is booming, the search for a direct medical cure remains frustratingly slow.

For decades, the medical world bet the house on antibody drugs like Lecanemab and Donanemab. These drugs target and clear out amyloid-beta, a sticky protein that clumps together in the brains of Alzheimer’s patients. But recent real-world trials show they offer only modest benefits while carrying serious risks of brain bleeding and swelling. Tragically, these side effects hit ApoE4 gene carriers the hardest, meaning the people who need the drugs the most are at the greatest risk of being harmed by them. These disappointing results have led many scientists to question whether clearing sticky proteins is really the secret to curing the disease at all.

What about GLP-1 weight-loss jabs, the modern medical miracle for waistlines? Early observational studies hinted that people using them had a lower risk of dementia. However, a proper randomised trial showed they offer no benefit to people who already have Alzheimer’s. They might help prevent the rot by tackling obesity and diabetes in mid-life, but they are not a cure once the brain behinds to fade.

Still, scientists are not giving up. In a gym in central Helsinki, a group of grey-haired women in lycra are laughing, swinging kettlebells, and lifting weights. They are part of the groundbreaking MET-FINGER trial. This study combines lifestyle coaching with metformin (a cheap, safe diabetes drug) to see if the combination can delay or prevent mental decline. Elsewhere, researchers are throwing everything from saunas to ice baths at the problem, hunting for any edge that keeps the mind sharp.

Can we actually see a future where dementia rates drop?

We must be realistic: because our populations are ageing so rapidly, the absolute number of people living with dementia will likely continue to rise for a while yet.

But the pace of that growth is slowing dramatically, and the tools to bend the curve even further are already in our hands. The math of human ageing hides a wonderful secret: after age 70, the risk of dementia doubled roughly every five years. That means if we can use blood pressure pills, better hearing aids, gym sessions, and shingles jabs to delay the average onset of dementia by just five years, we would instantly slice total case numbers in half.

Push that delay a little further, and the total number of dementia patients in rich counties could soon begin to fall outright.

We are no longer helpless pawns waiting for a terrifying diagnosis. My own grandfather had Alzheimer’s, and family lore is full of stories about my father hunting for their car that my granddad forgot where he left. Yet the old man is cheeky: sometimes he would deliberately feign a moment of not being lucid just so my grandmother could play with him, asking him about his wife. He would wink at my dad and proceed to glaze my grandmother.

It’s a warm story but it does spark the dread of genetics loading the dice for me. But from the latest research, it seems like that’s just my handicap, not my destiny. The future of our brains is largely up to us, and the outlook has never been brighter.